R. Martin Chavez

R. Martin Chavez is a director of Alphabet Inc. (40 filings) and Recursion Pharmaceuticals, Inc. (17), and was Executive Vice President, CFO at Goldman Sachs Group Inc, where the record's 15 sales sit, worth EUR 5.0 million with a median of EUR 327,510. The three largest fall at the end of January and the start of February 2018: EUR 829,367 on February 7, EUR 752,829 and EUR 687,691 on January 31. No purchase appears.

The 74 filings, published from December 29, 2017 to September 16, 2026, are mostly 55 grants, with 1 option exercise and 3 lines of another kind. The pace is uneven: 15 filings in 2018, then 5 in 2021, 6 in 2022 and 2023, 11 in 2024, 15 again in 2025 and 14 in 2026. In all, 18 fall in the last twelve months, none of them a sale.

At Goldman Sachs Group Inc, Brian J. Lee, David A. Viniar, David M. Solomon, John F.W. Rogers and Pablo J. Salame each have 15 of Chavez's market trades within 30 days of one of theirs, in the same direction.